Overview

• Zynex Q3 revenue fell 73% yr/yr, missing analyst expectations

• Company reported a Q3 net loss of $42.9 mln, impacted by asset impairment charges

Outlook

• Zynex exploring strategic alternatives, including capital raising and restructuring

• Company enters 30-day grace period for $1.5 mln interest payment

Result Drivers

• TRICARE PAYMENT SUSPENSION - Revenue decline attributed to Tricare payment suspension and $2.8 mln revenue reduction during suspension period

• CLAIM SUBMISSION CHANGES - Changes to payer claim submissions and review practices led to denials and payment delays, impacting revenue

• WORKFORCE REDUCTIONS - Workforce reductions in early 2025 negatively impacted device orders, new patient onboarding, and revenue

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Zynex Inc is $2.85, about 80.1% above its November 14 closing price of $0.57

Press Release: ID:nPn6Ry2tfa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)